HER2+ Breast Cancer: Applying Recent Data Updates to Clinical Practice

A panel of experts discuss recent data updates on the treatment and management of HER2+ breast cancer and how these data may impact practice.

EP. 1: Evolving HER2+ Breast Cancer Care: Neo-Adjuvant Strategies and Treatment Goals

January 23rd 2024

Experts explore neoadjuvant HER2+ breast cancer care; delve into treatment goals, predictors, and personalized approaches; and uncover insights on chemotherapy, trastuzumab, and postoperative considerations.

EP. 2: Neoadjuvant Approaches in HER2+ Breast Cancer

January 23rd 2024

Experts discuss evidence-based strategies in neoadjuvant therapy for HER2+ breast cancer and provide insights on surgery-first considerations, disease size impact, and personalized preoperative regimens.

EP. 3: HER2+ Breast Cancer: Anthracycline Considerations

January 30th 2024

Experts discuss anthracycline use in HER2+ breast cancer and provide insights into how patient scenarios, heterogeneity, and neuropathy concerns shape considerations in diverse clinical situations.

EP. 4: Subcutaneous HER2+ Breast Cancer Treatment Trends

January 30th 2024

Experts discuss evolving practices in HER2+ breast cancer care, subcutaneous formulations, patient preferences, and resource conservation.

EP. 5: Adjuvant Strategies in HER2+ Brest Cancer: Timing and Tailoring

February 6th 2024

Health care professionals review considerations in transitioning breast cancer patients to the adjuvant setting and discuss response monitoring, treatment tailoring, and the evolving role of imaging.

EP. 6: Evolving Strategies in Adjuvant HER2+ Breast Cancer

February 6th 2024

Experts analyze adjuvant therapy based on preoperative responses. The discussion unveils standard practices, recent KATHERINE trial data, and considerations for residual disease, offering profound insights into tailoring treatment for improved outcomes.

EP. 7: Exploring Therapeutic Avenues in HER2+ Breast Cancer

February 13th 2024

Experts delve into post–KATHERINE trial discussions, examining data and its impact on residual disease. They highlight unmet needs, emphasizing the ongoing CompassHER2 RD trial’s potential to address challenges, especially regarding brain metastases.

EP. 8: Metastatic HER2+ Breast Cancer: Current Strategies and Ongoing Trials

February 13th 2024

Experts discuss the CLEOPATRA trial outcomes, taxane nuances, and evolving strategies in first-line treatment. They review practical considerations and ongoing trials and dive into the dynamic landscape of managing metastatic HER2+ breast cancer, anticipating transformative developments.

EP. 9: Navigating Second-Line Choices in HER2+ Breast Cancer

February 20th 2024

Health care professionals delve into the dynamic landscape of second-line treatments with insights from the DESTINY-Breast03 trial.

EP. 10: Decoding HER2+ Breast Cancer: Challenges in Brain Metastases

February 20th 2024

Experts explore the intricacies of managing brain metastases in HER2+ breast cancer and delve into the latest evidence, patient considerations, and evolving guidelines for this complex scenario.

EP. 11: Navigating HER2+ Brain Metastases: Emerging Insights

February 27th 2024

Experts share insights on cutting-edge data shaping HER2+ breast cancer care, from the paradigm-shifting HER2CLIMB trial to the promising TUXEDO-1 and ROSET-BD studies; they also uncover advancements in treating patients with brain metastases.

EP. 12: HER2+ Breast Cancer Treatment Dynamics and Challenges

February 27th 2024

Health care professionals discuss the evolving landscape of HER2+ breast cancer treatments, delving into the complexities of the HER2CLIMB trial and strategies for third- and fourth-line interventions.

EP. 13: Navigating Treatment Challenges in HER2+ Breast Cancer

March 5th 2024

Experts analyze the complexities of HER2+ breast cancer treatment, exploring options in the third-line setting and the evolving landscape of antibody-drug conjugates.

EP. 14: Insights and Challenges in Advancing HER2+ Breast Cancer Care

March 5th 2024

Experts review groundbreaking advancements in HER2+ breast cancer treatment, covering curative strategies, metastatic challenges, and the need for ongoing innovation to enhance patient outcomes.